Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 1999;81:33–40.
Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997;28:2442–2447.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432–1437.
Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al. Effect of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). JACC 2002;39:610–616.
McCully KS. Vascular pathology of hyperhomocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111–122.
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149–1155.
Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395–1398.
McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. Circulation 1999;99:2383–2388.
Willinek WA, Ludwig M, Lennarz M, Holler T, Stumpe KO. Highnormal serum homocysteine concentrations are associated with an increased risk of early atherosclerotic carotid artery wall lesions in healthy subjects. J Hypertens 2000;18:425–430.
Folsom AR, Neito FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart diseases incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998;98:204–210.
Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618–625.
Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430–436.
Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary disease. JAMA 1992;268:68–72.
Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae: specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87:1130–1134.
Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983–986.
Campbell LA, O’Brien ER, Cappuccio AL, Kuo CC, Wang SP, Stewart D, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissue. J Infect Dis 1995;172:585–588.
Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP 3rd, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628–633.
Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614–1620.
Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathol 1996;21:215–221.
Maeda N, Sawayama Y, Tatsukawa M, Shimizu C, Kashiwagi S, Hayashi J. Chlamydia pneumoniae seropositivity and early carotid atherosclerosis in a suburban Japanese population. Atherosclerosis 2002;164:313–319.
Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992;94:89–91.
Lobo A, Naso A, Arheart K, Kruger WD, Abou-Ghazala T, Alsous F, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol 1999;83:821–825.
Sawayama Y, Tatsukawa M, Okada K, Maeda N, Shimizu C, Kikuchi K, et al. Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins. Atherosclerosis 2003;171:281–285.
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–809.
Stanger OH, Semmelrock HJ, Rehak P, Tiran B, Meinitzer A, Rigler B, et al. Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease. Atherosclerosis 2003;166:409.
Donnelly JG, Pronovost C. Evaluation of the Abbott Imx fluorescence polarization immunoassay and the Bio-Rad enzyme immunoassay for homocysteine: comparison with high-performance liquid chromatography. Ann Clin Biochem 2000;37:194–198.